Related Experiment Videos
[Clinical evaluation of a new oral cephem, cefdinir, in children]
Insights
Cefdinir (CFDN) is a safe and effective antibiotic for treating common childhood infections. Clinical trials show 100% efficacy in evaluable cases, with a recommended dosage to minimize side effects.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Pharmacology
- Antimicrobial Therapy
Background:
- Bacterial infections are a common concern in pediatric populations.
- Evaluating new antibiotic options for children is crucial for effective treatment.
- Cefdinir (CFDN) is a third-generation cephalosporin with broad-spectrum activity.
Purpose of the Study:
- To assess the safety, efficacy, and pharmacokinetics of Cefdinir (CFDN) in pediatric patients.
- To determine optimal dosing regimens for Cefdinir in children.
- To identify potential adverse effects associated with Cefdinir treatment in children.
Main Methods:
- A study involving 28 pediatric patients was conducted.
- Evaluated clinical response, adverse effects, and pharmacokinetic profiles.
- Included patients with respiratory, middle ear, urinary, and soft tissue infections.
Main Results:
- Cefdinir demonstrated 100% efficacy in 22 evaluable cases.
- Recommended daily dosage: 9-18 mg/kg, divided into three portions.
- Increased dosage correlated with a higher incidence of gastrointestinal side effects.
Conclusions:
- Cefdinir (CFDN) is deemed safe and effective for treating pediatric infections caused by susceptible bacteria, including Staphylococcus aureus.
- The suggested dosing regimen balances efficacy with tolerability.
- Further research may explore Cefdinir's role in specific pediatric infectious disease contexts.
Abstract:
Cefdinir (CFDN, FK482) was evaluated for its safety, efficacy and pharmacokinetics in 28 children. CFDN was effective in 100% of 22 evaluable cases with respiratory, middle ear, urinary or soft tissue infections. From the clinical response, adverse effects and the pharmacokinetic results, daily dose of 9-18 mg/kg, administered in 3 divided portions is suggested. Increase of dose will be associated with increase of gastrointestinal side effects. The data suggest that CFDN is safe and effective when used in children with infections caused by susceptible bacteria including Staphylococcus aureus.